SCHEMBL22501419

SCHEMBL22501419

C=C(c1ccncc1)c1ccc2ccccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ CNR2 P34972 3/20 0.49
▸ MGAM O43451 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ AR P10275 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PFKFB3 Q16875 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ KDM4E B2RXH2 4/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ NFKB1 P19838 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28605670 0.87 CNR2 (0.62) RAB9ANPC1CNR2MGAMCYP1A2
SCHEMBL28443611 0.83 MGAM (0.61) RAB9ANPC1CNR2MGAMCYP1A2
SCHEMBL11316978 0.78 CNR2 (0.69) RAB9ANPC1CNR2MGAMCYP1A2
SCHEMBL22501398 0.76 KDM4E (0.66) RAB9ANPC1CNR2MGAMKDM4E
SCHEMBL3860500 0.76 HSD17B14 (0.52) RAB9ANPC1CNR2MGAMHDAC6
SCHEMBL8746411 0.74 CNR2 (0.47) RAB9ANPC1CNR2MGAMKDM4E
SCHEMBL27828157 0.74 CNR2 (0.44) RAB9ACNR2MGAMKDM4EHDAC8
SCHEMBL12256867 0.74 MGAM (0.64) RAB9ANPC1CNR2MGAMCYP1A2
SCHEMBL2480615 0.73 MGAM (0.50) RAB9ANPC1CNR2MGAMCYP1A2
SCHEMBL28437810 0.73 RAB9A (0.46) RAB9ANPC1CNR2MGAMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479803-B2 Antimalarial compounds UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-11-25 — — US disclosed
US-20220204452-A1 ANTIMALARIAL COMPOUNDS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2022-06-30 — — US disclosed
WO-2020206252-A1 ANTIMALARIAL COMPOUNDS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479803-B2 Antimalarial compounds H1-3, FPR3, NHERF1 RAB9A 1335/4885NPC1 51/4885CNR2 987/4885
US-20220204452-A1 ANTIMALARIAL COMPOUNDS H1-3, FPR3, NHERF1 RAB9A 1335/4885NPC1 51/4885CNR2 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback